文献速递白血病

一线接受或未接受三氧化二砷治疗的t-APL患者特征与结局

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
PubMed 文献 · Leukemia · 2017-03-21

该研究纳入103例成人t-APL患者,分别接受ATRA单药、ATRA联合ATO、ATRA联合化疗或三者联合方案。含ATO方案完全缓解率更高、早期死亡率更低;以ATO为基础的治疗无事件生存率显著优于CTX/ATRA(95% vs 78%,P=0.042),但2年总生存无差异(88%,P=0.47)。

要点

  • 含ATO方案诱导完全缓解率100%和95%,早期死亡率0%和5%。
  • 以ATO为基础治疗的无事件生存率95%,显著高于CTX/ATRA的78%(P=0.042)。
  • 强化治疗患者2年总生存率88%,不同治疗组间无差异(P=0.47)。

核心结论

  • 在t-APL中,ATRA联合ATO或CTX/ATRA方案可行,且较CTX/ATRA方案带来更好的结局。

研究设计与样本

  • 回顾性评估103例接受治疗的成人t-APL患者,按一线方案分为ATRA单药(n=7)、ATRA联合ATO(n=24)、ATRA联合CTX(n=53)及三者联合(n=19)四组。

主要发现

  • 诱导治疗后完全缓解率:ATRA单药57%、ATO/ATRA 100%、CTX/ATRA 78%、CTX/ATO/ATRA 95%。
  • 早期死亡率:ATRA单药43%、ATO/ATRA 0%、CTX/ATRA 12%、CTX/ATO/ATRA 5%。
  • 3例复发,2例发生治疗相关急性髓系白血病,13例缓解期死亡(其中7例为原发恶性肿瘤复发)。
  • 生存随访中位时间3.7年;ATRA单药治疗者无一人存活超过1年。
  • 在删失因原发恶性肿瘤复发死亡后,以ATO为基础治疗的无事件生存率为95%(95%CI 82-99%),显著高于CTX/ATRA的78%(95%CI 64-87%;P=0.042)。

临床怎么用

  • 作者认为在t-APL中,ATRA联合ATO或CTX/ATRA方案可行,且较CTX/ATRA方案带来更好的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kayser S, Krzykalla J, Elliott MA, et al. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia. 2017. PMID: 28322237. doi:10.1038/leu.2017.92

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。